MAX A. CHERNESKY, Ph.D.; JAMES B. MAHONY, Ph.D.; IAIN O. STEWART, M.B., Ch.B., F.R.C.P.(C); BARBARA J. BROWN, R.N.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Hepatitis B vaccine (Heptavax B, Merck, Sharp & Dohme, West Point, Pennsylvania) was licensed in 1981, and early studies reported seroconversion rates over 90% after administration of three intramuscular doses. More recent studies have reported poor seroconversion rates, ranging from 60.6% to 74% (1-4). The vaccine manufacturer and the Centers for Disease Control have gathered data to show differences in seroconversion rates according to the site of injection (5). Among hospitals that reported suboptimal responses, the pooled response rate was 88% for those using arm injection and 73% for those giving injections in the buttock.
Since initiating
CHERNESKY MA, MAHONY JB, STEWART IO, et al. Seroconversion After Hepatitis B Vaccination. Ann Intern Med. 1986;105:293. doi: https://doi.org/10.7326/0003-4819-105-2-293_1
Download citation file:
© 2020
Published: Ann Intern Med. 1986;105(2):293.
DOI: 10.7326/0003-4819-105-2-293_1